Drug Approval | October 13, 2021
Dr Reddy’s launch anti-cancer drug in China
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
The agreement will sharpen Cigna's focus on the growth path for its rapidly expanding global health portfolio
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
The company will use the capital for building its team, product development, marketing, and setting up in-school clinics to deliver connected health to one million families
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
Lifebit's accompanying suite of AI-powered end-to-end software solutions provide faster data insights, accelerate drug discovery pipelines, and improve clinical trials success
Since its inception, over three million users have used MFine services with the platform clocking over three lakh monthly transactions
The company operates in over eight cities and the start-up plans to expand its reach to over 100 non-metro cities in the next 18-24 months
The startup’s AI platform uses AI algorithms to automatically detect abnormalities and diseases in medical images, reducing patient misdiagnosis and increasing radiologists’ productivity
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
Subscribe To Our Newsletter & Stay Updated
